ロード中...
Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Lymphoproliferative Disorders
INTRODUCTION: Chemoimmunotherapeutic regimens using the anti-CD20 antibody rituximab improved significantly the survival rates in various B-cell lymphoproliferative disorders (LPDs), including chronic lymphocytic leukemia (CLL). The next-generation CD20 antibody obinutuzumab represents an addition t...
保存先:
| 出版年: | Expert Opin Biol Ther |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166403/ https://ncbi.nlm.nih.gov/pubmed/28893099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1377178 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|